01:19:34 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-19 Bokslutskommuniké 2024
2024-10-24 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-23 Ordinarie utdelning AROC 0.00 SEK
2024-05-22 Årsstämma 2024
2024-05-03 Kvartalsrapport 2024-Q1
2024-02-22 Bokslutskommuniké 2023
2023-11-02 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-25 Ordinarie utdelning AROC 0.00 SEK
2023-05-24 Årsstämma 2023
2023-05-03 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-17 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning AROC 0.00 SEK
2022-05-24 Årsstämma 2022
2022-04-29 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2022-01-19 Extra Bolagsstämma 2022
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-31 Kvartalsrapport 2021-Q2
2021-06-03 Extra Bolagsstämma 2021
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-07 Ordinarie utdelning AROC 0.00 SEK
2021-05-06 Årsstämma 2021
2021-02-19 Bokslutskommuniké 2020
2020-11-19 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-15 Kvartalsrapport 2020-Q1
2020-05-07 Ordinarie utdelning AROC 0.00 SEK
2020-05-06 Årsstämma 2020
2020-02-21 Bokslutskommuniké 2019
2019-11-08 Extra Bolagsstämma 2019
2019-11-05 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-05-17 Ordinarie utdelning AROC 0.00 SEK
2019-05-16 Årsstämma 2019
2019-05-16 Kvartalsrapport 2019-Q1
2019-02-22 Bokslutskommuniké 2018
2018-11-09 Kvartalsrapport 2018-Q3
2018-08-31 Kvartalsrapport 2018-Q2
2018-06-18 Ordinarie utdelning AROC 0.00 SEK
2018-06-15 Årsstämma 2018
2018-04-27 Kvartalsrapport 2018-Q1
2018-02-22 Bokslutskommuniké 2017
2017-11-23 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-19 Ordinarie utdelning AROC 0.00 SEK
2017-05-18 Årsstämma 2017
2017-05-11 Kvartalsrapport 2017-Q1
2017-02-16 Bokslutskommuniké 2016
2016-11-17 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-19 Ordinarie utdelning AROC 0.00 SEK
2016-05-18 Årsstämma 2016
2016-05-10 Kvartalsrapport 2016-Q1
2016-02-16 Bokslutskommuniké 2015
2015-11-10 Kvartalsrapport 2015-Q3
2015-08-25 Kvartalsrapport 2015-Q2
2015-06-04 Ordinarie utdelning AROC 0.00 SEK
2015-06-03 Årsstämma 2015
2015-05-28 Kvartalsrapport 2015-Q1
2015-02-17 Bokslutskommuniké 2014
2014-11-18 Kvartalsrapport 2014-Q3
2014-08-19 Kvartalsrapport 2014-Q2
2014-05-08 Ordinarie utdelning AROC 0.00 SEK
2014-05-07 Årsstämma 2014
2014-05-05 Kvartalsrapport 2014-Q1
2014-02-18 Bokslutskommuniké 2013
2013-11-27 Kvartalsrapport 2013-Q3
2013-08-21 Kvartalsrapport 2013-Q2
2013-05-06 Ordinarie utdelning AROC 0.00 SEK
2013-05-03 Årsstämma 2013
2013-04-24 Kvartalsrapport 2013-Q1
2013-02-19 Bokslutskommuniké 2012
2012-11-20 Kvartalsrapport 2012-Q3
2012-08-21 Kvartalsrapport 2012-Q2
2012-06-13 Ordinarie utdelning AROC 0.00 SEK
2012-06-12 Årsstämma 2012
2012-05-22 Kvartalsrapport 2012-Q1
2012-03-05 Extra Bolagsstämma 2012
2012-02-09 Bokslutskommuniké 2011
2011-10-17 Kvartalsrapport 2011-Q3
2011-08-17 Kvartalsrapport 2011-Q2
2011-06-01 Kvartalsrapport 2011-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
AroCell är specialiserade inom onkologi och bakteriologi. Bolaget har en bred produktportfölj, och utvecklar, marknadsför och säljer blod-, och urin provtester som används av sjukhus och kliniker. Testerna ämnar ge information för upptäckt av sjukdomar såsom urologiska cancerformer och tyfoidfeber. AroCell riktar sig till patientgrupper i olika delar av världen. Huvudkontoret ligger i Stockholm.
2023-11-02 08:00:00

A word from the CEO
”The first nine months have been highly favorable for AroCell, with almost a 40% increase in sales compared to previous years. During the third quarter, AroCell continues to experience a growing order intake in both bacteriology and oncology. To address the growing demand, we are consistently increasing our production capacity, both through internal expansion and in collaboration with our partners. As a result of increased demand and a temporary extension of delivery times with suppliers, we are experiencing a shift in revenue recognition from the third quarter to future periods. Simultaneously, the work to automate several of our biomarkers is progressing as planned. I am pleased to report that we are in a good position to take the company further in its growth.”

Anders Hultman, CEO

Reporting period July 1st – September 30th

  • Net sales amounted to KSEK 10,700 (10,401).
  • Profit after financial items amounted to KSEK -13,003 (-11,069)*.
  • Cash flow from operating activities for the period amounted to KSEK -5,661 (-1,856).
  • Earnings per share before and after dilution amounted to SEK -0.06 (-0.05).
  • Cash and cash equivalents at the end of the period amounted to KSEK 51,512 (67,825).

* Includes costs for goodwill amortization of KSEK 9,895 (9,895) for the quarter.

Reporting period January 1st – September 30th

  • Net sales amounted to KSEK 33,528 (24,519).
  • Profit after financial items amounted to KSEK -42,161 (-42,779)*.
  • Cash flow from operating activities for the period amounted to KSEK -12,525 (-11,373).
  • Earnings per share before and after dilution amounted to SEK -0.18 (-0.20).
  • Cash and cash equivalents at the end of the period amounted to KSEK 51,512 (67,825).

* Includes costs for goodwill amortization of KSEK 29,684 (29,684) for the period.

Events during the period July 1st – September 30th

  • AroCell has signed an additional agreement with ZECEN Biotech for the development of its third tumor marker product, TK 210 ELISA, on ZECEN Biotech’s automated platforms. This collaboration is an important milestone for AroCell as the company strives to expand its product range and improve cancer diagnostics.
  • A recent study has been published, providing additional evidence for the use of UBC® Rapid as a diagnostic and monitoring tool for bladder cancer. This study stands as the first of its kind, comparing various commercial rapid tests among a large group of patients with bladder cancer and healthy individuals at a single center.
  • New study focused on the clinical applications of the TK 210 ELISA for ovarian cancer has been accepted for publication in the Karger Oncology journal. This study highlights the clinical utility of TK1-specific activity (TK1 SA) in the early detection of ovarian cancer.

Events after the period

  • After the conclusion of the period, the warrant program, as decided by the annual general meeting, has been implemented. The total number of warrants issued is 5,000,000, with a premium of 0.05 öre. The program has a duration of 3 years and is allocated among various groups, including the CEO, management team, other executives, and other employees. The strike price has been set at SEK 1, and the warrants are subscribed on market terms.

Interim report January 1st – September 30th, 2023 (Link)